HLN

Nostalgia-fueled experience introduces Excedrin Rapid Relief, providing fast relief of tough pain that starts in as little as 15 minutes Key Takeaways: Excedrin is introducing My Little Headache, a nostalgic digital-pet experience inspired by the handheld toys of the late '90s and early 2000s, capitalizing on the renewed popularity of digital pets among nostalgia-seeking consumers The interactive experience turns headache disruption into a playful, hard-to-ignore virtual pet that escalates through alerts, animations, and reactions As the digital pet becomes increasingly demanding, My Little Headache reminds consumers that headaches do not wait, and neither should relief. With Excedrin Rapid Relief's patented Fast Release Technology starting to provide relief in as little as 15 minutes, the pet transforms alongside the experience, playfully bringing to life the feeling of leaving headache pain behind and getting back to yourself Singer and actor Jesse McCartney helps bridge nostalgia and contemporary culture, reconnecting with longtime fans while building relevance with a new generation WARREN, N.J.

Goldman Sachs handpicks European stocks with the highest conviction for outperformance, and four of October's top selections carry a benefit most growth-focused investors overlook entirely.

Unilever PLC (LSE:ULVR) is on JP Morgan's 'positive watch', and Haleon PLC (LSE:HLN, NYSE:HLN) on 'negative watch', ahead of third-quarter reporting by European consumer staples companies. The note adds Givaudan to positive watch alongside Unilever, Heineken N.V.

Investors interested in stocks from the Consumer Products - Discretionary sector have probably already heard of Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two companies is the best option for those looking for undervalued stocks?

Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare group, is expected to reduce its 2026 organic sales growth guidance after UBS forecast a subdued third quarter and limited visibility over the cough and cold season. UBS expects Haleon to report organic sales growth of 3.1% for the three months to September, below Visible Alpha consensus of 3.5% and broadly unchanged from the second quarter.

Deutsche Bank has reiterated its 'sell' rating on Haleon PLC (LSE:HLN, NYSE:HLN), warning that the consumer health group faces persistent pressure on growth even as it heads into the cold and flu season. The broker kept a 320p price target on the FTSE 100 company, whose brands include Sensodyne and Panadol, against a last close of 342.8p.

Investors with an interest in Consumer Products - Discretionary stocks have likely encountered both Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks offers value investors a better bang for their buck right now?

Investors interested in Consumer Products - Discretionary stocks are likely familiar with Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks presents investors with the better value opportunity right now?

Jefferies has raised its price target for Haleon (Haleon PLC (LSE:HLN, NYSE:HLN), the consumer health company behind Sensodyne and Advil, to 410p from 400p, maintaining its Buy rating. The broker highlighted a 70 basis point margin beat in the first half of the year, though it warned this revived concerns about whether Haleon was investing enough behind growth.

LONDON, Aug. 19, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the pricing terms, expiration and results of the offer to buy back any and all of the outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 (the "Notes") of Haleon US Capital LLC's (the "Offeror"), the Company's wholly owned subsidiary (the "Tender Offer"). The Tender Offer has been made upon the terms and subject to the conditions set forth in the Offer to Purchase dated 11 August 2026 (the "Offer to Purchase").